Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 3Unknown 2Terminated 2Recruiting 2Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 7Genitourinary 4Thoracic 3Other hematologic neoplasm 2Breast 2Sarcoma 1Other solid neoplasm 1Lymphoid 1

Conditions

Estrogen Receptor Positive Breast Cancer 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 87Cyclophosphamide 67Capecitabine 67Paclitaxel 64Docetaxel 58Fulvestrant 52Letrozole 50Carboplatin 42pembrolizumab 41Lapatinib 38Doxorubicin 36Anastrozole 32Vinorelbine 31Bevacizumab 31exemestane 28Tamoxifen 25Gemcitabine 25Albumin-Bound Paclitaxel 25Radiotherapy 21Taxes 19atezolizumab 18pertuzumab 17Everolimus 17130-nm albumin-bound paclitaxel 17Epirubicin 16palbociclib 15Magnetic Resonance Spectroscopy 15eribulin 14Ado-Trastuzumab Emtansine 14Goserelin 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hydroxychloroquine × Breast × Clear all
NCT00765765 2023-08-09

Ixabepilone and Hydroxychloroquine in Treating Patients With Metastatic Breast Cancer

Rutgers, The State University of New Jersey

Phase 1/2 Terminated
6 enrolled 7 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT02414776 2017-09-27

ABC01

Western Regional Medical Center

Phase 1 Terminated
3 enrolled
Breast

Estrogen Receptor Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡